[Molecular mechanism underlying differentiation of HL-60 cells induced by hexamethylene bisacetamide].

The objective of this study was to investigate the effect of hexamethylene bisacetamide (HMBA) on differentiation of HL-60 cells and its possible molecular mechanism. HL-60 cells were co-cultured with different concentrations of HMBA (0.5, 1, 2 mmol/L) for 4 days, then the proliferation was assayed by MTT at different time points. Wright-Giemsa staining was used to observe the change in morphology. Cell differentiation antigen CD11b expression and the altered distribution of cell cycle in HL-60 induced by HMBA were analyzed by flow cytometry. The expressions of c-myc, mad1, p21, p27, hTERT and HDAC1 mRNA were detected by RT-PCR. The results indicated that the proliferation of HL-60 cells was inhibited by HMBA in a time-and-dose-dependent manner. Upon 2 mmol/L HMBA treatment, the HL-60 cells arrested at G(0)/G(1) phase and differentiated into granular line in morphology, with the up-regulation of CD11b expression. The expression of c-myc and hTERT mRNA obviously down-regulated, the expression of p21, p27 and mad1 mRNA up-regulated, while there was no change of the expression of hTERT mRNA. It is concluded that effect of HMBA on the differentiation of HL-60 cells may partly contribute to switch from c-myc to mad1 expression, to up-regulate expressions of p21 and p27 mRNA, and down-regulate hTERT mRNA expression, while there is no relation with the expression of HDAC1 mRNA.

Down-regulation of TRRAP-dependent hTERT and TRRAP-independent CAD activation by Myc/Max contributes to the differentiation of HL60 cells after exposure to DMSO.

Myc/Max/Mad often play pivotal roles in the proliferation, apoptosis, differentiation and cell cycle progress of leukemia cells. Myc and Mad are known to be unstable proteins and their expression is tightly regulated throughout cell cycle progression and differentiation. Usually, c-Myc expression is implicated in cell growth and proliferation, and the deregulated expression of c-Myc in both myeloid leukemia cells and normal myeloid cells not only blocks terminal differentiation but also its associated growth arrest. HL60 cells could be induced to differentiate into mature granulocytes by DMSO in vitro, but the mechanism of this effect has not been elucidated clearly. We proposed the hypothesis that down-regulation of c-Myc expression by DMSO contributed to the differentiation of HL60 cells by way of activating target genes hTert and CAD. The results showed that c-Myc expression was down-regulated in differentiated HL60 cells but not in exponentially-growing HL60 cells, without or with the target gene activation of hTert and CAD, respectively. Further study indicated that hTert activation is TRRAP-dependent while CAD activation is TRRAP-independent. On the other hand, up-regulation of P(21) and P(27) and down-regulation of cyclinA and cyclinE also play important roles in induction of the terminal differentiation of HL60 cells. Our results support the hypothesis that c-Myc expression and activation of target genes for hTert and CAD play critical roles in the proliferation of HL60 cells, while down-regulation of c-Myc expression and activation of target genes for hTert and CAD contributed to the terminal differentiation of HL60 cells after exposure to DMSO in vitro.

Effect of arsenic trioxide on cytokine expression by acute promyelocytic leukemia cells.

OBJECTIVE: To detect the expression of cytokines by acute promyelocytic leukemia (APL) cells before and after exposure to arsenic trioxide. METHODS: Diagnoses were performed according to the FAB cytological classification criteria and cytogenetic criteria. Bone marrow or blood samples from APL patients were collected in heparinized tubes, then primary APL cells were separated by traditional Ficoll-Hypaque density centrifugation and purified after adherence to plastic surfaces. IL-1(beta), IL-6, IL-8, TNF alpha and G-CSF levels in the leukemia cell culture supernatants were detected by ELISA. At the same time, nitro blue tetrazolium (NBT) reduction test was used to detect the differentiation of APL cells. RESULTS: After 96 hours exposure to arsenic trioxide, 10 - 6 mol/L in vitro or 10 mg/d in vivo, APL cells showed a significant increase of IL-1(beta) (P < 0.05) and G-CSF (P < 0.05) production, and a significant decrease of IL-6 (P < 0.05) and IL-8 (P < 0.05). However, there was no obvious variation of TNF alpha when compared with APL cells without exposure to arsenic trioxide. On the other hand, the proliferation ratio of APL cells in vitro was statistically correlated to the IL-1(beta) secretion ratio or G-CSF secretion ratio. The cell number ratio in patients with detectable IL-1(beta) or G-CSF was higher than that without detectable IL-1(beta) or G-CSF. CONCLUSION: IL-1(beta) and G-CSF secretion may play an important role in the proliferation of APL cells after exposure to arsenic trioxide.

The role of donor hepatocytes and/or splenocytes pre-injection in reducing islet xenotransplantation rejection.

OBJECTIVE: To observe the effect of tail vein injection with donor hepatocyte and/or splenocyte on islets xenotransplantation rejection. METHODS: New-born male pigs and BALB/C mice were selected as donors and recipients respectively. Islets xenotransplantation was performed in recipients just after the third time of tail vein injection with donor hepatocytes and/or splenocytes. Macrophage phagocytosis, NK killing activity, T lymphocyte transforming function of spleen cells, antibody forming function of B lymphocytes, and T lymphocyte subsets were taken to monitor transplantation rejection. The effects of this kind of transplantation were indicated as variation of blood glucose and survival days of recipients. RESULTS: Streptozotocin (STZ) succeeded in inducing diabetes mellitus models of mice. Pre-injection of donor hepatocytes, and splenocytes or their mixture via tail vein was effective in preventing donor islets transplantation from rejection, which was demonstrated by the mentioned immunological marks. And each group of transplantation could decrease the blood glucose of recipients and prolong the survival days. Pre-injection of mixture of donor hepatocytes and splenocytes was more effective in preventing rejection than pre-injection of donor hepatocytes or splenocytes separately. CONCLUSION: We propose that pre-injection of donor hepatocytes, splenocytes separately or their mixture before donor islets transplantation is a good way to prevent rejection.